Bessemer Group Inc. Has $3.62 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bessemer Group Inc. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 5,078 shares of the biopharmaceutical company’s stock after selling 174 shares during the period. Bessemer Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Virtu Financial LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $6,364,000. Morse Asset Management Inc increased its stake in shares of Regeneron Pharmaceuticals by 0.9% during the third quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company’s stock worth $5,053,000 after purchasing an additional 43 shares during the period. Anchor Investment Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 212.0% during the third quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company’s stock worth $902,000 after purchasing an additional 583 shares during the period. Sculati Wealth Management LLC lifted its holdings in Regeneron Pharmaceuticals by 1.9% during the 3rd quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company’s stock worth $1,970,000 after purchasing an additional 38 shares during the last quarter. Finally, Pine Valley Investments Ltd Liability Co boosted its stake in Regeneron Pharmaceuticals by 19.0% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company’s stock valued at $5,575,000 after purchasing an additional 848 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on REGN. Citigroup dropped their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Robert W. Baird decreased their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research report on Monday, March 31st. Finally, Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $966.88.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $554.18 on Friday. The stock has a 50-day moving average price of $659.94 and a two-hundred day moving average price of $755.22. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The company has a market capitalization of $60.59 billion, a PE ratio of 14.48, a P/E/G ratio of 2.34 and a beta of 0.44. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business earned $11.86 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.64%. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.